EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Impact of biological/targeted versus conventional synthetic disease‐modifying antirheumatic drugs on patient‐reported outcomes in rheumatoid arthritis

Masafumi Sugiyama, Saki Okuda‐Tsuchimoto, Takashi Tsuchimoto, Koji Kinoshita, Itaru Matsumura

Rheumatology & Autoimmunity · 2026-06 · 6 (2) · 94-104

DOI: 10.1002/rai2.70048 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Rheumatology & Autoimmunity, online erschienen am 22.04.2026. Verfasst von Masafumi Sugiyama und 4 weiteren Autor:innen. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In patients with rheumatoid arthritis (RA), patient‐reported outcomes (PROs) may vary by disease‐modifying antirheumatic drug (DMARD) class. This study aimed to assess the impact of biological/targeted synthetic DMARDs (b/tsDMARDs) on PROs in patients with sustained low RA activity or remission, compared with those treated with conventional synthetic DMARDs (csDMARDs) alone.

Methods

A retrospective cross‐sectional study was conducted on patients who maintained low RA activity or remission for at least 6 months. PROs, including the Short Form‐36, Health Assessment Questionnaire, EuroQol 5 Dimensions, Routine Assessment of Patient Index Data 3, and Functional Assessment of Chronic Illness Therapy–Fatigue scale, were assessed and compared between patients treated with csDMARDs alone and those treated with b/tsDMARDs with or without methotrexate (MTX).

Results

This study enrolled 102 patients with RA, and found that patients treated with antitumor necrosis factor‐alpha inhibitors had better PROs compared with those treated with csDMARDs alone, particularly in role physical (coefficient: 5.37, 95% confidence interval [CI]: 0.35–10.39), role emotional (coefficient: 5.78, 95% CI: 1.04–10.52), vitality (coefficient: 5.23, 95% CI: 0.57–9.90) and mental health (coefficient: 5.58, 95% CI: 1.37–9.79). Similarly, treatment with interleukin‐6 receptor inhibitors and Janus kinase inhibitors resulted in superior PROs in role physical (coefficient: 5.76 [95% CI: 0.06–11.48] and 8.99 [95% CI: 1.97–16.01], respectively) compared with csDMARDs. Furthermore, MTX use was associated with improvements in vitality (coefficient: 4.34, 95% CI: 0.14–8.54) and mental health (coefficient: 4.59, 95% CI: 0.82–8.35). Conclusion b/tsDMARDs, particularly tumor necrosis factor‐alpha inhibitors, provide superior PROs in patients with sustained RA low activity or remission, with additional benefits from MTX.

Zitieren

APA

Sugiyama, M., Okuda‐Tsuchimoto, S., Tsuchimoto, T., Kinoshita, K., & Matsumura, I. (2026). Impact of biological/targeted versus conventional synthetic disease‐modifying antirheumatic drugs on patient‐reported outcomes in rheumatoid arthritis. Rheumatology & Autoimmunity, 6(2), 94-104. https://doi.org/10.1002/rai2.70048

Vancouver

Sugiyama M, Okuda‐Tsuchimoto S, Tsuchimoto T, Kinoshita K, Matsumura I. Impact of biological/targeted versus conventional synthetic disease‐modifying antirheumatic drugs on patient‐reported outcomes in rheumatoid arthritis. Rheumatology & Autoimmunity. 2026;6(2):94-104. doi:10.1002/rai2.70048

BibTeX
@article{Sugiyama2026,
  author = {Sugiyama, Masafumi and Okuda‐Tsuchimoto, Saki and Tsuchimoto, Takashi and Kinoshita, Koji and Matsumura, Itaru},
  title = {Impact of biological/targeted versus conventional synthetic disease‐modifying antirheumatic drugs on patient‐reported outcomes in rheumatoid arthritis},
  journal = {Rheumatology & Autoimmunity},
  year = {2026},
  volume = {6},
  number = {2},
  pages = {94--104},
  doi = {10.1002/rai2.70048}
}
Kostenlos starten →